Insider Buying: Rapport Therapeutics (NASDAQ:RAPP) Director Acquires $99,991.71 in Stock

Posted by Brian Himes on Oct 25th, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) Director Wendy Young bought 3,789 shares of Rapport Therapeutics stock in a transaction that occurred on Thursday, October 22nd. The stock was purchased at an average price of $26.39 per share, for a total transaction of $99,991.71. Following the acquisition, the director directly owned 13,289 shares of the company’s stock, valued at $350,696.71. The trade was a 39.88% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Rapport Therapeutics Price Performance

Rapport Therapeutics stock opened at $25.93 on Friday. The stock’s 50-day moving average is $39.01 and its 200-day moving average is $38.93. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -8.53 and a beta of 1.22. Rapport Therapeutics, Inc. has a 12 month low of $23.75 and a 12 month high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Research analysts anticipate that Rapport Therapeutics, Inc. will post -4.08 EPS for the current year.

Institutional Investors Weigh In On Rapport Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RAPP. KBC Group NV acquired a new stake in shares of Rapport Therapeutics during the first quarter worth approximately $30,000. Sterling Capital Management LLC increased its stake in shares of Rapport Therapeutics by 597.9% in the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after buying an additional 843 shares during the last quarter. State of Wyoming acquired a new stake in Rapport Therapeutics in the second quarter valued at $65,000. Meeder Asset Management Inc. acquired a new stake in Rapport Therapeutics in the second quarter valued at $116,000. Finally, AlphaCentric Advisors LLC raised its holdings in Rapport Therapeutics by 6.8% in the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock valued at $201,000 after acquiring an additional 408 shares in the last quarter.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on RAPP shares. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Raymond James Financial restated a “strong-buy” rating and set a $86.00 target price on shares of Rapport Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a report on Tuesday, October 20th. William Blair assumed coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating for the company. Finally, Guggenheim increased their price target on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $68.36.

View Our Latest Research Report on Rapport Therapeutics

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.